ZAI LAB 09688Hong Kong Stock Exchange

19.2500.31%( +0.060 )
Closed: Oct 9 · Delayed · Hong Kong Stock Exchange
ZAI LAB (09688) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2020-09-28
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG9887T1168
Southbound Connect
Shanghai · Shenzhen

Industry

Innovative Drugs & Biologics 0.02%
124 stocks in this industry
Down 52 Up 57
Industry RankingsValue (HKD)Rank
Revenue (Last FY)25.38B9/112
Net Profit (Last FY)-9.68B124/125
ROE (Last FY)-24.53%84/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
再鼎医药有限公司 Executive Director
杜莹 Executive Director
Leon O. Moulder, Jr. Executive Director
John Diekman Independent Non-Executive Director
Richard Gaynor Independent Non-Executive Director
梁颖宇 Independent Non-Executive Director
William Lis Independent Non-Executive Director
Scott W. Morrison Independent Non-Executive Director
Michel Vounatsos Independent Non-Executive Director
Peter Wirth Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-03-05.

About this page

This page shows ZAI LAB (09688) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.